Teva’s Austedo Fails In Tourette’s Syndrome
Growth Driver Held Back In New Indication
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
